邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

药物基因组学的临床部署策略及流程

王飞,  武志慧,  闵浩巍,  余乐,  姜召芸,  朱翀,  弓孟春,  史文钊,  朱卫国,  向炎珍

downloadPDF
文章导航 > 协和医学杂志  > 2020 >  11(4): 443-448
王飞, 武志慧, 闵浩巍, 余乐, 姜召芸, 朱翀, 弓孟春, 史文钊, 朱卫国, 向炎珍. 药物基因组学的临床部署策略及流程[J]. 协和医学杂志, 2020, 11(4): 443-448. doi: 10.3969/j.issn.1674-9081.2020.04.015
引用本文: 王飞, 武志慧, 闵浩巍, 余乐, 姜召芸, 朱翀, 弓孟春, 史文钊, 朱卫国, 向炎珍. 药物基因组学的临床部署策略及流程[J]. 协和医学杂志, 2020, 11(4): 443-448. doi: 10.3969/j.issn.1674-9081.2020.04.015
shu
Fei WANG, Zhi-hui WU, Hao-wei MIN, Le YU, Zhao-yun JIANG, Chong ZHU, Meng-chun GONG, Wen-zhao SHI, Wei-guo ZHU, Yan-zhen XIANG. Clinical Deployment Strategies and Processes for Pharmacogenomics[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 443-448. doi: 10.3969/j.issn.1674-9081.2020.04.015
Citation: Fei WANG, Zhi-hui WU, Hao-wei MIN, Le YU, Zhao-yun JIANG, Chong ZHU, Meng-chun GONG, Wen-zhao SHI, Wei-guo ZHU, Yan-zhen XIANG. Clinical Deployment Strategies and Processes for Pharmacogenomics[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 443-448. doi: 10.3969/j.issn.1674-9081.2020.04.015
shu

药物基因组学的临床部署策略及流程

doi: 10.3969/j.issn.1674-9081.2020.04.015
  • 1.

    神州数码医疗科技股份有限公司, 北京 100080

  • 2.

    北京协和医院信息中心, 北京 100730

  • 3.

    北京协和医院全科医学科(普通内科), 北京 100730

  • 4.

    中国医学科学院 北京协和医学院 北京协和医院, 北京 100730

基金项目: 

中国医学科学院医学与健康科技创新工程 2016-I2M-2-004

中国医学科学院罕见病研究中心资助项目 2016ZX310174-4

详细信息
    通讯作者:

    朱卫国  电话:010-69154149, E-mail:zhuwg@pumch.cn

    向炎珍  电话:010-69155806, E-mail:xiangyz@pumch.cn

  • 中图分类号: R968;R969.3

Clinical Deployment Strategies and Processes for Pharmacogenomics

  • 1.

    Digital China Health Technologies Corporation Limited, Beijing 100080, China

  • 2.

    Department of Information Center, Peking Union Medical College Hospital, Beijing 100730, China

  • 3.

    Department of Primary Care and Family Medicine, Peking Union Medical College Hospital, Beijing 100730, China

  • 4.

    Peking Union Medical College Hospital, Chinesse Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要: 随着测序技术的飞速发展, 临床上积累了大量个体化用药案例, 相应的循证医学数据日益丰富, 促进了药物基因组学的快速发展, 然而只有在临床上进行规范合理的部署, 才能发挥其价值。药物基因组学的临床部署目前主要有被动执行和预先执行两种策略, 具体流程实施涉及电子病历整合、基因-药物对的选择、药物经济学评价、教育培训等多个方面。本文主要对药物基因组学的临床部署策略及实施流程进行综述, 并对其面临的挑战进行讨论, 以期为我国药物基因组学的临床部署提供指导。
    Abstract: With the rapid development of sequencing technology, a large number of clinical cases with personalized medicine have been accumulated. Abundant evidence-based medical data have promoted the rapid development of pharmacogenomics. However, it could play an important role only if it would be deployed in clinical practice. There are two strategies for the clinical deployment of pharmacogenomics:reactive strategy and preemptive strategy. Different deployment strategies require different deployment processes. The specific implementation process involves the integration of EMR, selection of gene-drug pairs, cost-effectiveness, education and training, etc. This paper reviewed the strategies and implementation workflow of pharmacogenomics clinical deployment, and discussed the challenges so as to provide guidance for the clinicaldeployment of pharmacogenomics in China.
    利益冲突  无
    • HTML全文
    • 参考文献(32)
  • [1] 中华人民共和国国家卫生和计划生育委员会.药物代谢酶和药物作用靶点基因检测技术指南(试行)[S].国卫医医护便函[2015]第240号.
    [2] 中华人民共和国国家卫生和计划生育委员会.肿瘤个体化治疗检测技术指南(试行)[S].国卫医医护便函[2015]第240号.
    [3] Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation:current programs in five US medical centers[J]. Annu Rev Pharmacol Toxicol, 2015, 55:89-106. doi:  10.1146/annurev-pharmtox-010814-124835
    [4] Carpenter JS, Rosenman MB, Knisely MR, et al. Pharmacogenomically actionable medications in a safety net health care system[J]. SAGE Open Med, 2016, 4:2050312115624333. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Doaj000004720487
    [5] Jaja C, Bowman L, Wells L, et al. Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management[J]. Clin Transl Sci, 2015, 8:272-280. doi:  10.1111/cts.12260
    [6] Saldivar JS, Taylor D, Sugarman EA, et al. Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility[J]. Pharmgenomics Pers Med, 2016, 9:1-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725634/
    [7] Finkelstein J, Friedman C, Hripcsak G, et al. Potential utility of precision medicine for older adults with polypharmacy:a case series study[J]. Pharmgenomics Pers Med, 2016, 9:31-45.
    [8] Schildcrout JS, Denny JC, Bowton E, et al. Optimizing Drug Outcomes Through Pharmacogenetics:A Case for Preemptive Genotyping[J]. Clin Pharmacol Ther, 2012, 92:235-242. doi:  10.1038/clpt.2012.66
    [9] Plumpton CO, Roberts D, Pirmohamed M, et al. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions[J]. Pharmacoeconomics, 2016, 34:771-793. doi:  10.1007/s40273-016-0397-9
    [10] Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10, 000 patients with preemptive pharmacogenomic testing[J]. Clin Pharmacol Ther, 2014, 95:423-431. doi:  10.1038/clpt.2013.229
    [11] 阳国平, 郭成贤.药物基因组学与个体化治疗用药决策[M].北京:人民卫生出版社, 2016.
    [12] Shuldiner AR, Relling MV, Peterson JF, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program:overcoming challenges of real-world implementation[J]. Clin Pharmacol Ther, 2013, 94:207-210. doi:  10.1038/clpt.2013.59
    [13] 孙可欣, 詹思延, 胡永华.医学大数据在药物基因组学领域中的应用与发展[J].药物流行病学杂志, 2017, 26:68-73. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=ywlxbxzz201701018
    [14] Rasmussentorvik LJ, Stallings SC, Gordon AS, et al. Design and Anticipated Outcomes of the eMERGE-PGx Project:A Multicenter Pilot for Preemptive Pharmacogenomics in Electronic Health Record Systems[J]. Clin Pharmacol Ther, 2014, 96:482-489. doi:  10.1038/clpt.2014.137
    [15] Demmer LA, Waggoner DJ. Professional Medical Education and Genomics[J]. Annu Rev Genomics Hum Genet, 2014, 15:507-516. doi:  10.1146/annurev-genom-090413-025522
    [16] Nickola TJ, Green JS, Harralson AF, et al. The current and future state of pharmacogenomics medical education in the USA[J]. Pharmacogenomics, 2012, 13:1419-1425. doi:  10.2217/pgs.12.113
    [17] 许景峰.药物基因组学应用于临床药学是个体化用药的必然趋势[J].药学服务与研究, 2009, 9:161-165. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=yxfwyyj200903001
    [18] Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment:are we there yet?[J]. Pharmacogenomics J, 2017, 17:395-402. doi:  10.1038/tpj.2017.21
    [19] 谭重庆, 彭六保, 曾小慧, 等.药物基因组学领域药物经济学评价的问题探讨[J].中国医院药学杂志, 2016, 36:1339-1342. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgyyyx201616001
    [20] Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity:A pharmacoeconomic analysis based on a target case[J]. J Am Acad Dermatol, 2000, 42:628-632. doi:  10.1067/mjd.2000.103980
    [21] Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P4502C19 genetic polymorphism[J]. Clin Pharmacokinet, 2002, 41:913-958. doi:  10.2165/00003088-200241120-00002
    [22] Chou WH, Yan FX, De LJ, et al. Extension of a pilot study:impact from the cytochrome P4502D6 polymorphism on outcome and costs associated with severe mental illness[J]. J Clin Psychopharmacol, 2000, 20:246-251. doi:  10.1097/00004714-200004000-00019
    [23] Priest VL, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease[J]. Pharmacoeconomics, 2006, 24:767-781. doi:  10.2165/00019053-200624080-00004
    [24] Perlis RH, Ganz DA, Avorn J, et al. Pharmacogenetic testing in the clinical management of schizophrenia:a decision-analytic model[J]. J Clin Psychopharmacol, 2005, 25:427-434. doi:  10.1097/01.jcp.0000177553.59455.24
    [25] Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients:a cost-effectiveness analysis[J]. Pharmacogenet Genomics, 2006, 16:139-147. doi:  10.1097/01.fpc.0000189801.96220.82
    [26] Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2004, 20:593-599. doi:  10.1111/j.1365-2036.2004.02124.x
    [27] Me VDAM, Gurwitz D, Detmar SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice:a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe[J]. Pharmacogenomics, 2006, 7:783-792. doi:  10.2217/14622416.7.5.783
    [28] Maitland-van der Zee AH, Klungel OH, Stricker BH, et al. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men[J]. Pharmacogenetics, 2004, 14:53-60. doi:  10.1097/00008571-200401000-00006
    [29] Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment:enabling reuse for clinical research[J]. J Am Med Inform Assoc, 2013, 20:144-151. doi:  10.1136/amiajnl-2011-000681
    [30] Zhang J, Johnson TR, Patel VL, et al. Using usability heuristics to evaluate patient safety of medical devices[J]. J Biomed Inform, 2003, 36:23-30. doi:  10.1016/S1532-0464(03)00060-1
    [31] 柴怡, 赵俊, 孙宁生, 等.医学伦理审查规范流程的探讨[C].中华医学会第12次全国医学科学研究管理学学术年会, 2010, 153-156.
    [32] 王维嘉.医学伦理委员会规范运行中应注意的几个问题[C].中华医学会医学伦理学分会学术年会, 2007, 284-286.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  619
  • HTML全文浏览量:  211
  • PDF下载量:  234
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-06-19
  • 刊出日期:  2020-07-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！